NORTHERN TRUST CORP - CRINETICS PHARMACEUTICALS IN ownership

CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 72 filers reported holding CRINETICS PHARMACEUTICALS IN in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.3%.

Quarter-by-quarter ownership
NORTHERN TRUST CORP ownership history of CRINETICS PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$17,764,416
+100.9%
597,324
+21.7%
0.00%
+50.0%
Q2 2023$8,842,955
+15.4%
490,730
+2.8%
0.00%0.0%
Q1 2023$7,665,245
-12.9%
477,288
-0.7%
0.00%0.0%
Q4 2022$8,798,640
-6.3%
480,800
+0.5%
0.00%0.0%
Q3 2022$9,395,000
+4.0%
478,382
-1.2%
0.00%0.0%
Q2 2022$9,032,000
-6.6%
484,281
+9.9%
0.00%0.0%
Q1 2022$9,669,000
-24.5%
440,524
-2.2%
0.00%0.0%
Q4 2021$12,800,000
+65.7%
450,528
+22.8%
0.00%
+100.0%
Q3 2021$7,725,000
+12.0%
366,999
+0.2%
0.00%0.0%
Q2 2021$6,900,000
+52.9%
366,114
+23.9%
0.00%0.0%
Q1 2021$4,512,000
+0.7%
295,393
-7.0%
0.00%0.0%
Q4 2020$4,481,000
-12.2%
317,536
-2.5%
0.00%0.0%
Q3 2020$5,103,000
+38.8%
325,681
+55.1%
0.00%0.0%
Q2 2020$3,677,000
+54.0%
209,930
+29.3%
0.00%0.0%
Q1 2020$2,387,000
-35.9%
162,345
+9.4%
0.00%0.0%
Q4 2019$3,725,000
+82.5%
148,442
+9.4%
0.00%
Q3 2019$2,041,000
-24.2%
135,649
+25.9%
0.00%
-100.0%
Q2 2019$2,694,000
+13.4%
107,744
+3.3%
0.00%0.0%
Q1 2019$2,375,000
+3.2%
104,329
+36.0%
0.00%0.0%
Q4 2018$2,301,000
+5.4%
76,727
+0.7%
0.00%0.0%
Q3 2018$2,184,00076,2290.00%
Other shareholders
CRINETICS PHARMACEUTICALS IN shareholders Q3 2020
NameSharesValueWeighting ↓
Saturn V Capital Management LP 623,819$11,336,5019.41%
Finepoint Capital LP 822,745$15,0564.87%
Bain Capital Life Sciences Investors, LLC 2,305,558$42,1924.72%
Opaleye Management Inc. 732,000$13,395,6004.66%
5AM Venture Management, LLC 862,286$15,779,8344.24%
SPHERA FUNDS MANAGEMENT LTD. 671,644$12,291,0852.64%
First Light Asset Management, LLC 1,329,313$24,326,4282.26%
BRAIDWELL LP 3,469,674$63,495,0342.13%
BVF INC/IL 2,736,613$50,080,0182.11%
Perceptive Advisors 4,039,276$73,918,7512.08%
View complete list of CRINETICS PHARMACEUTICALS IN shareholders